Use of Buprenorphine in Pennsylvania State Medicaid Programs

Researchers looked at predictors of buprenorphine treatment, patterns of care, and quality of care in the Pennyslvania State Medicaid Program.  Seperately they investigated optimal treatment duration for buprenorphine opioid agonst therapy, which varies by provider and payer decision-making. Researchers worked to identify distinct trajectories of buprenorphine use and examined associated outcomes.

Their findings were shared in two publications: 

-  Gordon AJ, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM. Patterns and Quality of Buprenorphine Opioid Against Treatment in a Large Medicaid Program. J Addict Med. 2015; 9(60: 470-7. PMID: 26517324.

- Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue JM. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016; 111(5): 892-902. PMID: 26662858.